Search results for "Beta-thalassemia"

showing 10 items of 52 documents

Hematopoietic stem cell function in b-thalassemia is impaired and is rescued by targeting the bone marrow niche

2020

Abstract Hematopoietic stem cells (HSCs) are regulated by signals from the bone marrow (BM) niche that tune hematopoiesis at steady state and in hematologic disorders. To understand HSC-niche interactions in altered nonmalignant homeostasis, we selected β-thalassemia, a hemoglobin disorder, as a paradigm. In this severe congenital anemia, alterations secondary to the primary hemoglobin defect have a potential impact on HSC-niche cross talk. We report that HSCs in thalassemic mice (th3) have an impaired function, caused by the interaction with an altered BM niche. The HSC self-renewal defect is rescued after cell transplantation into a normal microenvironment, thus proving the active role of…

MaleStromal cellImmunologybone marrow mice thalassemia hematopoietic stem cells transplantation parathyroid hormoneSettore MED/08 - Anatomia PatologicaBiochemistryBone remodelingMiceBone MarrowmedicineAnimalsHumansOsteopontinStem Cell NicheHematopoietic stem cell β-thalassemia the bone marrow nichebiologybeta-ThalassemiaHematopoietic stem cellCell BiologyHematologyHematopoietic Stem CellsHematopoiesisMice Inbred C57BLTransplantationHaematopoiesismedicine.anatomical_structurebiology.proteinCancer researchFemaleBone marrowStem cell
researchProduct

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspi…

2009

The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control …

MaleThalassemiaKaplan-Meier Estimatelaw.inventionchemistry.chemical_compoundRandomized controlled triallawCause of DeathNeoplasmsDeferiproneProspective StudiesChildCause of deathHazard ratioHematologyMiddle AgedCombined Modality TherapySurvival RateThalassemia survival chelation treatment trial thalassemia majorCombinationSplenectomyMolecular MedicineDrug Therapy CombinationFemaleDeferiproneAdultmedicine.medical_specialtyAdolescentPyridonesDeferoxamineIron Chelating AgentsYoung AdultDrug TherapyInternal medicinemedicineHumansBlood TransfusionAdolescent; Adult; Blood Transfusion; Cause of Death; Chelation Therapy; Child; Combined Modality Therapy; Deferoxamine; Drug Therapy; Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Kaplan-Meiers Estimate; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prospective Studies; Pyridones; Splenectomy; Survival Rate; Young Adult; beta-ThalassemiaMolecular BiologySurvival rateKaplan-Meiers EstimateSurvival analysisProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modelbeta-ThalassemiaCell Biologymedicine.diseaseChelation TherapySurgerychemistrybusiness
researchProduct

Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone Dur…

2003

The purpose of this study was to evaluate if the variations of heart magnetic resonance imaging in beta-thalassemia major patients treated with Deferoxamine B mesylate (DF) or Deferiprone (L1) chelation therapy is a useful tool of the indirect myocardial iron content determination. For this reason, a prospective study was carried out. Seventy-two consecutive patients with beta-thalassemia major (35 treated with DF and 37 with L1) were studied. The main outcome results were laboratory parameters including determination of the liver iron concentration (LIC) and magnetic resonance imaging (MRI) of the heart and liver. The heart to muscle signal intensity ratios (HSIRs) were significantly incre…

Malemedicine.medical_specialtyLiver Iron ConcentrationPyridonesIronThalassemiaClinical BiochemistryAdministration OralDeferoxamineIron Chelating AgentsGastroenterologychemistry.chemical_compoundInternal medicinemedicineHumansDeferiproneInfusions ParenteralChelation therapyProspective cohort studyGenetics (clinical)medicine.diagnostic_testbusiness.industryMyocardiumbeta-ThalassemiaBiochemistry (medical)Beta thalassemiaMagnetic resonance imagingHematologymedicine.diseaseMagnetic Resonance ImagingDeferoxaminechemistryHeart Function TestsPatient ComplianceFemalebusinessDeferipronemedicine.drugHemoglobin
researchProduct

Nonsense-mediated decay mechanism is a possible modifying factor of clinical outcome in nonsense cd39 beta thalassemia genotype

2012

Nonsense-mediated mRNA decay (NMD) is a surveillance system to prevent the synthesis of non-functional proteins. In β-thalassemia, NMD may have a role in clinical outcome. An example of premature translation stop codons appearing for the first time is the β-globin cd39 mutation; when homozygous, this results in a severe phenotype. The aim of this study was to determine whether the homozygous nonsense cd39 may have a milder phenotype in comparison with IVS1,nt110/cd39 genotype. Genotypes have been identified from a cohort of 568 patients affected by β-thalassemia. These genotypes were compared with those found in 577 affected fetuses detected among 2292 prenatal diagnoses. The…

Pediatricsmedicine.medical_specialtymedia_common.quotation_subjectNonsense-mediated decayNonsenseBeta thalassemiaBiologynonsense-mediated mRNA decay; beta-thalassemia; clinical outcame; beta-globin gene mutationsmedicine.diseaseGastroenterologynonsense-mediated mRNA decay beta-thalassemia beta-globin gene mutationsnonsense-mediated mRNA decay beta-thalassemia clinical outcame beta-globin gene mutations.Internal medicineGenotypemedicineDiseases of the blood and blood-forming organsRC633-647.5media_commonThalassemia Reports
researchProduct

Pattern of cognitive impairment in beta-thalassemia major

2000

Settore MED/26 - Neurologiacognitive beta-thalassemia major
researchProduct

Hematopoietic Stem Cell Mobilization for Gene Therapy: The Combination of G-CSF+Plerixafor in Patients with Beta-Thalassemia Major Provides High Yiel…

2015

Abstract Hematopoietic stem cell engineering is a promising therapy to cure b-thalassemia, in particular for patients who lack a suitable BM donor for allogeneic transplantation. Since the engrafted gene-corrected stem cells will not have any selective advantage over the unmodified ones, the effectiveness of the therapy in this setting largely depends on the infusion of high numbers of gene-modified cells and on the conditioning regimen. The quality of the infused cells is also crucial for the clinical outcome and the duration of the therapeutic effect. HSPCs mobilization, particularly when G-CSF and plerixafor are used in combination, has been proved to be the optimal approach to harvest a…

business.industryPlerixaforImmunologyHematopoietic stem cellHematopoietic Stem Cell Mobilization Gene Therapy Beta-Thalassemia.Cell BiologyHematologyLeukapheresisCD38PharmacologyBiochemistryCXCR4Granulocyte colony-stimulating factorSettore BIO/18 - Geneticamedicine.anatomical_structureImmunologyMedicineStem cellbusinessHematopoietic Stem Cell Mobilizationmedicine.drug
researchProduct

Cytoprotective effects of the antioxidant phytochemical indicaxanthin in beta-thalassemia red blood cells

2006

Antioxidant phytochemicals are investigated as novel treatments for supportive therapy in beta-thalassemia. The dietary indicaxanthin was assessed for its protective effects on human beta-thalassemic RBCs submitted in vitro to oxidative haemolysis by cumene hydroperoxide. Indicaxanthin at 1.0-10 microM enhanced the resistance to haemolysis dose-dependently. In addition, it prevented lipid and haemoglobin (Hb) oxidation, and retarded vitamin E and GSH depletion. After ex vivo spiking of blood from thalassemia patients with indicaxanthin, the phytochemical was recovered in the soluble cell compartment of the RBCs. A spectrophotometric study showed that indicaxanthin can reduce perferryl-Hb ge…

congenital hereditary and neonatal diseases and abnormalitiesAntioxidantErythrocytesPyridinesmedicine.medical_treatmentindicaxanthinphytochemicalBiochemistryHemolysisAntioxidantschemistry.chemical_compoundHemoglobinsAntioxidants betalainhemic and lymphatic diseasesSettore BIO/10 - BiochimicamedicineBenzene DerivativesHumansVitamin ETraditional medicineDose-Response Relationship DrugChemistrybeta-ThalassemiaBeta thalassemiaGeneral Medicinemedicine.diseaseLipid MetabolismGlutathionehaemoglobinBetaxanthinsPhytochemicalBiochemistryCytoprotectionSpectrophotometryCase-Control StudiesHeminAntioxidants betalains haemoglobin indicaxanthin phytochemicals red blood cellsIndicaxanthinOxidation-Reductionred blood cells
researchProduct

Alterations of panoramic radiomorphometric indices in children and adolescents with beta-thalassemia major: A fractal analysis study

2021

Background Beta-thalassemia major is an inherited disorder that can cause bone deformity and loss of bone mineral density. The objective of this study is to evaluate the cortical and trabecular mandibular bone morphology of children and adolescents who have beta-thalassemia major (ß-TM) using a fractal dimension (FD) analysis and different panoramic radiomorphometric indices with digital panoramic radiographic images (DPRIs). Material and Methods The study included 80 patients (with 40 patients each of ß-TM and control). The mandibular cortical width (MCW), panoramic mandibular index (PMI), mandibular cortical index (MCI), and simple visual estimation (SVE) were evaluated, and an FD analysi…

malignant transformationAdolescentResearchbeta-ThalassemiamirnasbiomarkersMandibleMedically compromised patients in Dentistryoral leukoplakiaoral squamous cell carcinomaFractalsOtorhinolaryngologyBone Densitymental disordersRadiography PanoramicHumansSurgeryChildGeneral DentistryUNESCO:CIENCIAS MÉDICASMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Iron Chelation Therapy in thalassaemia major: a sistematic review with meta-analyses of 1520 patients included on randomized clinical trials

2011

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using χ2 (Q) and I2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p<0.0001), increases in serum ferritin levels during DFX 5, 1…

medicine.medical_specialtyPyridonesIronMEDLINEThalassemiaSiderophoresDeferoxamineIron Chelating AgentsChelation treatment thalassaemia clinical trials iron overload meta-analysisBenzoatesGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansVentricular FunctionDeferiproneMolecular BiologyRandomized Controlled Trials as TopicEjection fractionbusiness.industryMyocardiumbeta-ThalassemiaDeferasiroxBeta thalassemiaCell BiologyHematologyTriazolesmedicine.diseaseChelation TherapySurgeryDeferoxamineDeferasiroxTreatment OutcomeLiverchemistryMeta-analysisFerritinsMolecular MedicineDrug Therapy CombinationbusinessDeferipronemedicine.drug
researchProduct

Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients.

2008

Increased expression of fetal haemoglobin (HbF) may ameliorate the clinical course of beta-thalassemia and sickle cell disease. Some pharmacological agents, such as hydroxycarbamide (HC), can increase fetal haemoglobin synthesis during adult life. Cellular selection and/or molecular mechanisms have been proposed to account for this increase. To explore the mechanism of action of HC we focused on homozygous Hb-Lepore patients that presented with high fetal haemoglobin levels and were good responders to HC treatment "in vivo". We performed primary erythroid cultures from peripheral blood of four homozygous Lepore patients. The increase in HBG (gamma-globin) transcription levels and HbF conten…

medicine.medical_specialtyTranscription GeneticHemoglobins AbnormalBiologyBlood cellHydroxycarbamideErythroid CellsTranscription (biology)hemic and lymphatic diseasesInternal medicineFetal hemoglobinmedicineHumansHydroxyureaGlobinRNA MessengerCells CulturedFetal HemoglobinIn Situ Hybridization FluorescenceHematologybeta-ThalassemiaHematologyMolecular biologyGlobinsRed blood cellmedicine.anatomical_structureCell culturemedicine.drugBritish journal of haematology
researchProduct